

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 May 2001 (10.05.2001)

PCT

(10) International Publication Number
WO 01/32170 A1

(51) International Patent Classification⁷: A61K 31/40,
31/52, 31/415

(21) International Application Number: PCT/US00/40901

(22) International Filing Date:
13 September 2000 (13.09.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/153,586 13 September 1999 (13.09.1999) US

(71) Applicant and

(72) Inventor: SWOPE, David, M. [US/US]; 266 East Crescent, Redlands, CA 92373 (US).

(74) Agents: FARAH, David, A. et al.; Sheldon & Mak, 9th Floor, 225 South Lake Avenue, Pasadena, CA 91101 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,

DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— With international search report.

— Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/32170 A1

(54) Title: COMPOSITION AND METHOD FOR DECREASING NEUROLOGIC SYMPTOMATOLOGY

(57) Abstract: A method of decreasing the signs or symptomatology in a patient with a neurologic condition or disease, or in a patient due to effects of exposure to an exogenous substance, such as a pharmaceutical agent, comprising selecting a patient having at least one sign or symptom selected from the group consisting of akinesia, bradykinesia, dyskinesias, gait disturbances, posture disturbances, rigid limbs, speech impairments and tremor and administering to the patient one or more than one effective doses of a phosphodiesterase inhibitor. A composition for decreasing the signs or symptomatology in a patient with a neurologic condition or disease, or in a patient due to effects of exposure to an exogenous substance, such as a pharmaceutical agent, the composition comprising an effective dose of one or more than one phosphodiesterase inhibitor combined with an effective dose of one or more than one additional pharmaceutical agent known to decrease signs or symptomatology in a patient with a neurologic condition or disease.

COMPOSITION AND METHOD FOR DECREASING NEUROLOGIC SYMPTOMATOLOGY

CROSS-REFERENCE TO RELATED APPLICATION

This Application takes priority from United States Provisional Patent Application 60/153,586, filed September 13, 1999 and entitled "Method of Treating Neurologic Disease," the contents of which are incorporated in this disclosure by reference in its entirety.

BACKGROUND

Parkinson's Disease is a chronic, progressive, neurodegenerative disease of unknown cause. It is characterized by tremor, rigidity, slowness of movement and loss of postural reflexes. Disability from Parkinson's Disease results from the progressive impairment of mobility, as well as a form of dementia that often accompanies the disease.

Parkinson's Disease is more common in the elderly population, with a peak incidence between the ages of 55 and 60. The prevalence of Parkinson's Disease rises with increasing age. The disease is found worldwide and is estimated to affect 1% of the population of the United States.

The primary biochemical abnormality in Parkinson's Disease is a progressive loss of dopamine producing cells in the substantia nigra pars compacta area of the brain. These cells are located in the midbrain and project to the striatum. The cells synapse with striatal neurons using dopamine as a neurotransmitter. The loss of dopamine associated with the cell loss results in an imbalance in the inhibitory and excitatory circuitry in the basal ganglia, and this in turn results in impairment of movement characteristic of Parkinson's Disease.

There is no known cure for Parkinson's Disease, but several forms of symptomatic treatment are available. These treatments include medication and surgery.

The principal goal of symptomatic treatment is to restore the normal balance of neurotransmitters in the basal ganglia. The most potent medication available for the treatment of Parkinson's Disease is levodopa. Levodopa is the biochemical precursor to dopamine. It can be taken orally and it crosses the blood-brain barrier where it is taken up by dopaminergic cells in the brain. Levodopa is then converted to dopamine which is released.

Levodopa is very effective in ameliorating the symptoms of Parkinson's Disease

5 during the early stages of the disease. However, potentially debilitating complications occur with chronic use of levodopa. For example, chronic use of levodopa causes its duration of action to progressively decrease, which causes patients to get cyclical fluctuations of Parkinson's Disease, symptoms known as "motor fluctuations." Additionally, chronic use of levodopa causes dyskinesias, which consists of random, purposeless movements or fixed postures. Such complications afflict approximately 50% of patients taking levodopa for more than five years.

The cause of levodopa complications is unknown but appears to be related to post-synaptic changes due to the pulsatile delivery of dopamine to the dopamine receptors.

10 Dyskinesias are particularly difficult to treat. Treatments include adjustment in levodopa doses to optimize the patient's response. However, while decreasing the dose reduces the dyskinesias, it usually results in worsening of the underlying symptoms of Parkinson's Disease. Amantidine hydrochloride administration is effective in reducing the duration and severity of dyskinesias in some patients but it is associated with confusion and nausea, among 15 other side effects. Further, surgical treatments such as pallidotomy and deep brain stimulation, are effective treatments for dyskinesias in some patients but these procedures are expensive and are associated with surgical complications themselves.

20 Therefore, there is a need for a new treatment for Parkinson's Disease that has fewer complications than current treatments. Further, there is a need for a new treatment for the complications associated with levodopa administration such as dyskinesias.

SUMMARY

25 A method of decreasing the signs or symptomatology in a patient with a neurologic condition or disease, or in a patient due to effects of exposure to an exogenous substance, such as a pharmaceutical agent. The method comprises selecting a patient having at least one sign or symptom selected from the group consisting of akinesia, bradykinesia, dyskinesias, gait disturbances, posture disturbances, rigid limbs, speech impairments and tremor. Then, the patient is administered one or more than one effective doses of a phosphodiesterase inhibitor such that the at least one sign or symptom improves.

30 In one embodiment, the patient selected is newly diagnosed with a neurologic disease or condition. In another embodiment, the patient selected has been taking medication or has had a surgical treatment and is experiencing dyskinesias. In a preferred embodiment, the signs or symptomatology are due to effects of exposure to levodopa.

In a preferred embodiment, the condition or disease is selected from the group consisting of dystonia, Huntington's Disease, multiple system atrophy, tardive dyskinésias and Tourette Syndrome. In a particularly preferred embodiment, the condition or disease is Parkinson's Disease.

5 In another preferred embodiment, the phosphodiesterase inhibitor is selected from the group consisting of caffeine, dipyridamole and theophylline. In a particularly preferred embodiment, the phosphodiesterase inhibitor is sildenafil.

10 In one embodiment, the method comprises administering a plurality of doses of the phosphodiesterase inhibitor. In a particularly preferred embodiment, the phosphodiesterase inhibitor is sildenafil and where the dose of sildenafil administered is between about 10 mg per day and about 200 mg per day, more preferably about 50 mg per day and most preferably about 25 mg per day. In another particularly preferred embodiment, the dose of the phosphodiesterase inhibitor is titrated for the particular patient until the patient receives the smallest dose that will maximally decrease the signs or symptomatology without creating 15 unwanted side effects that outweigh the benefits of the phosphodiesterase inhibitor.

In another embodiment, the phosphodiesterase inhibitor is administered for between about one week and about twenty years, and more preferably for between about one year and about five years. In a preferred embodiment, the phosphodiesterase inhibitor is administered orally.

20 In one embodiment, the present invention is a composition for decreasing the signs or symptomatology in a patient with a neurologic condition or disease, or in a patient due to the effects of exposure to an exogenous substance, such as a pharmaceutical agent. The composition comprises an effective dose of one or more than one phosphodiesterase inhibitor combined with an effective dose of one or more than one additional pharmaceutical agent 25 known to decrease signs or symptomatology in a patient with a neurologic condition or disease. In a preferred embodiment, the phosphodiesterase inhibitor is sildenafil. In another preferred embodiment, the additional pharmaceutical agent is selected from the group consisting of an anticholinergic, a carbidopa/levodopa combination, a dopamine agonist, a catechol-o-methyl transferase inhibitor, levodopa, a monoamine oxidase type B inhibitor and 30 an NMDA receptor antagonist. The composition can also comprise at least one substance selected from the group consisting of a binding agent, a coloring agent, an enteric coating and a flavoring agent.

The present invention also includes a method of decreasing the signs or symptomatology in a patient with a neurologic condition or disease, or in a patient due to effects of exposure to an exogenous substance, such as a pharmaceutical agent, the method comprising administering a composition according to the present invention.

5 In another embodiment of the present invention, there is provided a method of treating patients with Parkinson's Disease. The method comprises selecting a patient with Parkinson's Disease and administering one or more than one effective dose of a phosphodiesterase inhibitor such that the at least one sign or symptom improves. The one or more than one effective dose of a phosphodiesterase inhibitor can comprise administering a 10 plurality of effective doses of the phosphodiesterase inhibitor.

In a preferred embodiment, the phosphodiesterase inhibitor is sildenafil. In a particularly preferred embodiment, the dose of sildenafil administered is between about 10 mg per day and about 200 mg per day, more preferably about 50 mg per day and most preferably about 25 mg per day.

15 In another embodiment of the present invention, there is provided a method of decreasing dyskinesias associated with a neurologic disease or with exposure to an exogenous substance, such as levodopa. The method comprises selecting a patient with a dyskinesia from a neurologic disease or from exposure to an exogenous substance, and administering one or more than one effective dose of a phosphodiesterase inhibitor, such as sildenafil.

DESCRIPTION

According to one embodiment of the present invention, there is provided a method of decreasing the signs or symptomatology in a patient with a neurologic condition or disease, such as Parkinson's Disease, or in a patient due to effects of exposure to an exogenous substance, such as a pharmaceutical agent. The method comprises selecting a patient with appropriate signs or symptomatology and administering one or more than one effective dose of a phosphodiesterase inhibitor, such as sildenafil.

30 According to another embodiment of the present invention, there is provided a composition for decreasing neurologic signs or symptomatology in a patient with a neurologic condition or disease, such as Parkinson's Disease, or in a patient due to effects of exposure to an exogenous substance, such as a pharmaceutical agent. The composition comprises one or more than one effective dose of a phosphodiesterase inhibitor, such as sildenafil, and one or more than one effective dose of another substance effective in decreasing neurologic signs or

symptomatology.

As used in this disclosure, "signs or symptomatology" means either signs, or symptomatology, or a combination of signs and symptomatology.

According to one embodiment of the present invention, there is provided a method of decreasing neurologic signs or symptomatology in a patient with a neurologic condition or disease or in a patient due to effects of exposure to an exogenous substance. The method is particularly useful in decreasing neurologic signs or symptomatology related to movement and balance, such as akinesia, bradykinesia, gait disturbances, posture disturbances, rigid limbs, speech impairments and tremor, as well as dyskinesias associated with long term exposure to pharmaceutical agents such as levodopa. The method is particularly useful in decreasing neurologic signs or symptomatology due to diseases and conditions such as Parkinson's Disease, tardive dyskinesias, Tourette Syndrome, Huntington's Disease, multiple system atrophy and dystonia, or subsequent to viral infections, or due to exposure to an exogenous substance such as MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) or to pharmaceutical agents used to treat neurologic diseases, such as levodopa. The method can also be used to treat other diseases and conditions which have similar signs or symptomatology as Parkinson's Disease.

The method comprises, first, selecting a patient having appropriate signs or symptomatology. The patient can be newly diagnosed with a neurologic disease or condition, or have been previously diagnosed with a neurologic disease or condition. In a preferred embodiment, the patient has been previously diagnosed with a neurologic disease or condition, has been taking medication or has had a surgical treatment for the neurologic disease or condition, and has still experienced signs or symptomatology or has had unwanted side effects of the medication or surgery, such as dyskinesias.

The patient is then administered one or more than one effective dose of a phosphodiesterase inhibitor. In a preferred embodiment, the phosphodiesterase inhibitor is selected from the group consisting of caffeine, dipyridamole and theophylline. In a particularly preferred embodiment, the phosphodiesterase inhibitor is sildenafil (Viagra®, available from Pfizer, Inc., New York, NY US).

In another preferred embodiment, the method includes administering a plurality of doses of the phosphodiesterase inhibitor. In a particularly preferred embodiment, the phosphodiesterase inhibitor is sildenafil and the dose of sildenafil administered is between

about 10 mg per day and about 200 mg per day, and more preferably the dose is 25 mg per day. However, as will be understood by those with skill in the art with reference to this disclosure, the dose should be titrated for the particular patient until the patient receives the smallest dose that will maximally decrease the signs or symptomatology without creating unwanted side effects that outweigh the benefits of the phosphodiesterase inhibitor.

5 In another preferred embodiment, the phosphodiesterase inhibitor is administered for between about one week and about twenty years. In a particularly preferred embodiment, the phosphodiesterase inhibitor is administered for between about one year and about five years.

In a preferred embodiment, the phosphodiesterase inhibitor is administered orally, 10 though other routes of administration are also within the scope of this invention, including administration by skin patch, subcutaneous injection, inhaled preparations and direct intravenous administration.

In a particularly preferred embodiment, the method of the present invention comprises 15 administering a plurality of doses of a composition according to the present invention. The composition comprises an effective dose of one or more than one phosphodiesterase inhibitor, such as sildenafil, and an effective dose of one or more than one other pharmaceutical agents that is effective in decreasing neurologic signs or symptomatology. In a particularly preferred embodiment, the one or more than one other pharmaceutical agents is an agent known to decrease dyskinesias associated with a neurologic disease or associated with the 20 exposure to an exogenous substance.

According to another embodiment of the present invention, there is provided a 25 composition for decreasing the signs or symptomatology in a patient with a neurologic condition or disease, such as Parkinson's Disease, or in a patient due to effects of exposure to an exogenous substance, such as a pharmaceutical agent. The composition comprises an effective dose of one or more than one phosphodiesterase inhibitor combined with an effective dose of one or more than one additional pharmaceutical agent known to decrease signs or symptomatology in a patient with a neurologic condition or disease. In a preferred embodiment, the additional pharmaceutical agent is selected from the group consisting of an anticholinergic, a carbidopa/levodopa combination, a dopamine agonist, a catechol-o-methyl transferase inhibitor, levodopa, a monoamine oxidase type B inhibitor and an NMDA receptor antagonist. Examples of suitable anticholinergics are trihexyphenidyl (available as 30 Artane® from Lederle Pharmaceutical Division, Pearl River, NY US), and benztropine

(available as Cogentin® from Merck and Co., West Point, PA US). Examples of suitable carbidopa/levodopa combinations are Sinemet® and Sinemet® CR, (both from Merck and Co., West Point, PA US). Examples of suitable dopamine agonists are pramipexole (available as Mirapex® from Pharmacia and Upjohn Co., Kalamazoo MI US), ropinirole (available as Requip® from SmithKline Beecham Pharmaceuticals, Philadelphia PA US), pergolide (available as Permax® from Athena Neurosciences Inc., San Francisco CA US) and bromocriptine (available as Parlodel® from Novartis Pharmaceuticals, Inc., East Hanover, NJ US). Examples of suitable catechol-o-methyl transferase inhibitors are tolcapone (available as Tasmar® from Roche Pharmaceuticals, Nutley, NJ US) and entacapone (available as Comtan® from Novartis Pharmaceuticals, Inc., East Hanover, NJ US). An example of a suitable monoamine oxidase type B inhibitor is selegiline (available as Eldepryl® from Somerset Pharmaceuticals, Inc., Tampa, FL US). An example of a suitable NMDA receptor antagonist is amantadine (available as Symmetrel® from Endo Pharmaceuticals Inc., Chadds Ford, PA US).

15 In a preferred embodiment, the composition comprises effective doses of a plurality of phosphodiesterase inhibitors, or effective doses of a plurality of other pharmaceutical agents, or both effective doses of a plurality phosphodiesterase inhibitors and effective doses of a plurality of other pharmaceutical agents.

20 In another preferred embodiment, the effective dose of the one or more than one other pharmaceutical agents is the same as the dose that would be given if the pharmaceutical agent was not combined with the phosphodiesterase inhibitor. In a particularly preferred embodiment, the effective dose of the one or more than one other pharmaceutical agent is between about one tenth and about ninth tenths of the dose that would be given if the pharmaceutical agent was not combined with the phosphodiesterase inhibitor. In another 25 particularly preferred embodiment, the effective dose of the one or more than one other pharmaceutical agent is about one half of the dose that would be given if the pharmaceutical agent was not combined with the phosphodiesterase inhibitor.

30 As will be understood by those with skill in the art with reference to this disclosure, the composition of the present invention can also comprise one or more than one additional substances, such a binding agent, a coloring agent, an enteric coating and a flavoring agent. The composition is preferably configured to be administered orally. However, it can also be configured to be administered by skin patch, subcutaneous injection, inhaled preparations or

direct intravenous administration, among other routes, as will be understood by those with skill in the art with reference to this disclosure.

EXAMPLE I

METHOD FOR DECREASING NEUROLOGIC SYMPTOMATOLOGY

5 A 60 year old, Caucasian, male patient who had Parkinson's Disease for twelve years and who suffered from severe dyskinesia affecting all his extremities and his head and neck for five years was treated with the method for decreasing neurologic symptomatology according to the present invention. Before beginning treatment according to the present method, the patient was taking 700 mg of levodopa per day. The patient was initially treated 10 with 50 mg of sildenafil per day. During treatment, his dyskinesias were significantly reduced and his dose of sildenafil was decreased to 25 mg of sildenafil and his dose of levodopa was reduced to between 300 and 400 mg per day. The patient's signs and symptoms of Parkinson's Disease remain significantly improved after more than one year of treatment according to the present method.

EXAMPLE II

METHOD FOR DECREASING NEUROLOGIC SYMPTOMATOLOGY

15 A 55 year old, Caucasian, male patient who had Parkinson's Disease for fifteen years and who suffered from tremor at rest and gait disturbance was treated with the method for decreasing neurologic symptomatology according to the present invention. Before beginning treatment according to the present method, the patient was taking levodopa 500 mg per day. The patient was initially treated with 25 mg of sildenafil per day. After five months of 20 treatment, his tremor had ceased and his gait disturbance had improved significantly and his dose of sildenafil was increased to 25 mg three times per day and his dose of levodopa was decreased to 250 mg per day. The patient's signs and symptoms of Parkinson's Disease 25 remain significantly improved after more than seven months of treatment.

EXAMPLE III

METHOD FOR DECREASING NEUROLOGIC SYMPTOMATOLOGY

Seven additional patients with Parkinson's Disease and dyskinesias were treated with sildenafil at a dose of 25 mg per day in addition to their usual Parkinson's 30 Disease medications. The patients were all Caucasian and ranged in age from between 55 to 70 years. Four of the patients were men and three were women. Five of the seven patients had significant improvement in their dyskinesias using a dose the 25 mg per day. None of

the patients demonstrated any significant side effects of sildenafil treatment or any worsening of their Parkinson's Disease symptoms, though one did report facial flushing.

5 Although the present invention has been discussed in considerable detail with reference to certain preferred embodiments, other embodiments are possible. Therefore, the scope of the appended claims should not be limited to the description of preferred embodiments contained herein.

I CLAIM:

1. A method of decreasing the signs or symptomatology in a patient with a neurologic condition or disease, or in a patient due to effects of exposure to an exogenous substance, such as a pharmaceutical agent, the method comprising:
 - 5 a) selecting a patient having at least one sign or symptom selected from the group consisting of akinesia, bradykinesia, dyskinesias, gait disturbances, posture disturbances, rigid limbs, speech impairments and tremor; and
 - b) administering to the patient one or more than one effective doses of a phosphodiesterase inhibitor such that the at least one sign or symptom improves.
 - 10 2. The method of claim 1, where the patient selected is newly diagnosed with a neurologic disease or condition.
 3. The method of claim 1, where the patient selected has been taking medication or has had a surgical treatment and is experiencing dyskinesias.
 - 15 4. The method of claim 1, where the signs or symptomatology are due to effects of exposure to levodopa.
 5. The method of claim 1, where the condition or disease is selected from the group consisting of dystonia, Huntington's Disease, multiple system atrophy, tardive dyskinesias and Tourette Syndrome.
 6. The method of claim 1, where the condition or disease is Parkinson's Disease.
 - 20 7. The method of claim 1, where the phosphodiesterase inhibitor is selected from the group consisting of caffeine, dipyridamole and theophylline.
 8. The method of claim 1, where the phosphodiesterase inhibitor is sildenafil.
 9. The method of claim 1, where administering to the patient one or more than one effective doses of a phosphodiesterase inhibitor comprises administering a plurality of doses 25 of the phosphodiesterase inhibitor.
 10. The method of claim 1, where the phosphodiesterase inhibitor is sildenafil and where the dose of sildenafil administered is between about 10 mg per day and about 200 mg per day.
 - 30 11. The method of claim 1, where the phosphodiesterase inhibitor is sildenafil and where the dose of sildenafil administered is about 50 mg per day.
 12. The method of claim 1, where the phosphodiesterase inhibitor is sildenafil and where the dose of sildenafil administered is about 25 mg per day.

13. The method of claim 1, where administering to the patient one or more than one effective doses of a phosphodiesterase inhibitor comprises titrating the dose for the particular patient until the patient receives the smallest dose that will maximally decrease the signs or symptomatology without creating unwanted side effects that outweigh the benefits of the phosphodiesterase inhibitor.

5 14. The method of claim 1, where administering to the patient one or more than one effective doses of a phosphodiesterase inhibitor comprising administering the phosphodiesterase inhibitor for between about one week and about twenty years.

10 15. The method of claim 1, where administering to the patient one or more than one effective doses of a phosphodiesterase inhibitor comprising administering the phosphodiesterase inhibitor for between about one year and about five years.

16. The method of claim 1, where administering to the patient one or more than one effective doses of a phosphodiesterase inhibitor comprising administering the phosphodiesterase inhibitor orally.

15 17. A composition for decreasing the signs or symptomatology in a patient with a neurologic condition or disease, or in a patient due to effects of exposure to an exogenous substance, such as a pharmaceutical agent, the composition comprising an effective dose of one or more than one phosphodiesterase inhibitor combined with an effective dose of one or more than one additional pharmaceutical agent known to decrease signs or symptomatology 20 in a patient with a neurologic condition or disease.

18. The composition of claim 17, where the phosphodiesterase inhibitor is sildenafil.

19. The composition of claim 17, where the additional pharmaceutical agent is selected from the group consisting of an anticholinergic, a carbidopa/levodopa combination, a dopamine agonist, a catechol-o-methyl transferase inhibitor, levodopa, a monoamine 25 oxidase type B inhibitor and an NMDA receptor antagonist.

20. The composition of claim 17, where the additional pharmaceutical agent is selected from the group consisting of amantadine, benztrapine, bromocriptine, entacapone, pergolide, pramipexole, ropinirole, selegiline, tolcapone, and trihexyphenidyl.

21. The composition of claim 17, where the dose of one or more than one 30 phosphodiesterase inhibitors is a plurality of doses of a phosphodiesterase inhibitor.

22. The composition of claim 17, where the dose of one or more than one additional pharmaceutical agents are doses of a plurality of pharmaceutical agents.

23. The composition of claim 17, additionally comprising at least one substance selected from the group consisting of a binding agent, a coloring agent, an enteric coating and a flavoring agent.

24. A method of decreasing the signs or symptomatology in a patient with a neurologic condition or disease, or in a patient due to effects of exposure to an exogenous substance, such as a pharmaceutical agent, the method comprising administering the composition of claim 17 to the patient.

25 A method of treating patients with Parkinson's Disease, comprising:

5 a) selecting a patient with Parkinson's Disease having at least one sign or symptom selected from the group consisting of akinesia, bradykinesia, dyskinesias, gait disturbances, 10 posture disturbances, rigid limbs, speech impairments and tremor;

10 b) administering one or more than one effective dose of a phosphodiesterase inhibitor such that the at least one sign or symptom improves.

26 The method of claim 25, where administering one or more than one effective dose of a phosphodiesterase inhibitor comprising administering a plurality of effective doses of the phosphodiesterase inhibitor.

27. The method of claim 25, where the phosphodiesterase inhibitor is sildenafil.

28. The method of claim 27, where the dose of sildenafil is between about 10 mg per day and 200 mg per day.

20 29. The method of claim 27, where the dose of sildenafil is 25 mg per day.

30 30. The method of claim 27, where the dose of sildenafil is 50 mg per day.

31. A method of decreasing dyskinesias associated with a neurologic disease or with 25 exposure to an exogenous substance, comprising:

32 a) selecting a patient with a dyskinesia from a neurologic disease or from exposure to an exogenous substance; and

25 b) administering one or more than one effective dose of a phosphodiesterase inhibitor.

33. The method of claim 31, where the administration step includes administering a 30 plurality of effective doses of the phosphodiesterase inhibitor.

34. The method of claim 31, where the phosphodiesterase inhibitor administered is

35 sildenafil.

36. The method of claim 33, where the dose of sildenafil is between about 10 mg per day and 200 mg per day.

35. The method of claim 33, where the dose of sildenafil is 25 mg per day.
36. The method of claim 33, where the dose of sildenafil is 50 mg per day.
37. The method of claim 31, where the exogenous substance is a pharmaceutical agent used to treat Parkinson's Disease.

5 38. The method of claim 31, where the exogenous substance is levodopa.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/40901

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) :A61K 31/40, 31/52, 31/415

US CL :514/252.16, 263, 264, 392, 424

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/252.16, 263, 264, 392, 424

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,712,282 A (IYO ET AL) 27 January 1998 (27/1/98), see entire document, especially column 3, lines 42-63 and column 4, lines 47-61.	1-7, 9, 13-17, 19-26, 31, 32, 37, 38
Y		----- 8, 10-12, 18, 27-30, 33-36
X	US 3,961,060 A (FUXE) 01 June 1976 (1/6/76), see entire document.	1-7, 9, 13-17, 19-26, 31, 32, 37, 38
Y		----- 8, 10-12, 18, 27-30, 33-36

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents .	*T*	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance		
B earlier document published on or after the international filing date	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
I document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed	*A*	document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
20 DECEMBER 2000	13 MAR 2001
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 308-3230	Authorized officer TERRY J. DEY FREDERICK KRASS Telephone No. (703) 308-1235 PARALEGAL SPECIALIST TECHNOLOGY CENTER 1800